Zhongsheng group's products are patented in Europe and plan to cover the world

On October 14, Guangdong Zhongsheng Pharmaceutical Co., Ltd (hereinafter referred to as "Zhongsheng") released the announcement on obtaining the European patent certificate, saying that it has received the patent certificate issued by the European Patent Office Patent name: quinoline derivatives as SMO inhibitors patent No.: 3124482 patent application date: March 16, 2015 patentee: Guangdong Zhongsheng Pharmaceutical Co., Ltd patent term: 20 years from the application date In addition, the announcement also informed that the patent is the compound patent of zsp1602 project, an innovative drug used by Zhongsheng to treat small cell lung cancer, gastric cancer, esophageal cancer and other malignant tumors, which belongs to the core patent of the project The patent project zsp1602 "phase I / II clinical research on the treatment of advanced malignant tumors with chemical class 1 new drug zsp1602" has been listed in the national "major new drug creation" science and technology major project The zsp1602 project is progressing smoothly, and phase I clinical trial is currently being carried out In addition, in combination with the project development plan, sentient beings will launch the European designated country entry into force procedure for the patent At present, the core patent of zsp1602 project compound has been granted by the United States, New Zealand, Canada, Singapore, Japan, South Korea, Israel, South Africa, China, Australia, Colombia, Europe and other countries / regions The global intellectual property protection system of zsp1602 project has been gradually improved This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.